Health CarePharmaceuticals & Biotechnology
  • Price (GBX)56.00
  • Today's Change0.00 / 0.00%
  • Shares traded77.13k
  • 1 Year change-68.89%
  • Beta-0.3028
Data delayed at least 20 minutes, as of Oct 18 2019 14:53 BST.
More ▼

Key statistics

On Friday, Mereo BioPharma Group plc (MPH:LSE) closed at 56.00, 40.00% above the 52 week low of 40.00 set on Jul 22, 2019.
52-week range
40.00Jul 22 2019212.00Oct 18 2018
Previous close56.00
Average volume93.49k
Shares outstanding97.96m
Free float77.70m
P/E (TTM)--
Market cap54.86m GBP
EPS (TTM)-0.4313
Data delayed at least 20 minutes, as of Oct 18 2019 14:53 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Mereo BioPharma Group plc shares was Sell at 305.00 on 09 Aug 2017Read the full article

Board of Directors


Dr. Denise Scots-Knight, CEO and Co-Founder


Richard Jones, CFO


Charles Sermon, GC and Co-Founder


Dr. Alastair MacKinnon, CMO and Co-Founder


John Richard, Head of Corporate Development and Co-Founder


Wills Hughes-Wilson, Head of Patient Access & Commercial Planning


Mereo BioPharma Group plc
1 Cavendish Place
United Kingdom

T: +44 (0)333 023 7300
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.